Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/50282
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTavitiya Sudjaritruken_US
dc.contributor.authorThira Sirisanthanaen_US
dc.contributor.authorVirat Sirisanthanaen_US
dc.date.accessioned2018-09-04T04:27:45Z-
dc.date.available2018-09-04T04:27:45Z-
dc.date.issued2011-01-01en_US
dc.identifier.issn15320987en_US
dc.identifier.issn08913668en_US
dc.identifier.other2-s2.0-79951679948en_US
dc.identifier.other10.1097/INF.0b013e3181f812f8en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79951679948&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/50282-
dc.description.abstractThe prevalence of hepatitis A virus (HAV) protective antibody in 98 Thai HIV-infected children who achieved immune recovery after antiretroviral therapy was 12.2%. After a 2-dose HAV vaccination, 98.8% (85 of 86 children) seroconverted. The geometric mean titer was 520.95 mIU/mL. In a multivariate analysis, female gender, age <12 years and higher CD4 lymphocyte count at enrollment were predicting factors for high (≥250 mIU/mL) HAV antibody response. © 2011 Lippincott Williams & Wilkins, Inc.en_US
dc.subjectMedicineen_US
dc.titleAntibody responses to hepatitis A virus vaccination in Thai HIV-infected children with immune recovery after antiretroviral therapyen_US
dc.typeJournalen_US
article.title.sourcetitlePediatric Infectious Disease Journalen_US
article.volume30en_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.